Literature DB >> 29292665

Salvage Surgery after Radiation Failure in T1/T2 Larynx Cancer: Outcomes following Total versus Conservation Surgery.

Shayan Cheraghlou1, Phoebe Kuo1, Saral Mehra1,2, Wendell G Yarbrough1,2,3, Benjamin L Judson1,2.   

Abstract

Objective After radiation failure for early T-stage larynx cancer, national guidelines recommend salvage surgery. Total laryngectomy and conservation laryngeal surgery with an open or endoscopic approach are both used. Beyond single-institution studies, there is a lack of evidence concerning the outcomes of these procedures. We aim to study whether treatment with conservation laryngeal surgery is associated with poorer outcomes than treatment with total laryngectomy as salvage surgery after radiation failure for T1/T2 larynx cancers. Study Design A retrospective study was conducted of adult squamous cell larynx cancer cases in the National Cancer Database diagnosed from 2004 to 2012. Setting Commission on Cancer cancer programs in the United States. Methods Demographic, facility, tumor, and survival variables were included in the analyses. Multivariate survival regressions as well as univariate Kaplan-Meier analyses were conducted. Results Slightly more than 7% of patients receiving radiotherapy for T1/T2 larynx cancers later received salvage surgery. Salvage with partial laryngectomy was not associated with diminished survival as compared with total laryngectomy. However, positive surgical margins were associated with worse outcomes (hazard ratio, 1.782; P = .001), and a larger percentage of patients receiving partial laryngectomy had positive margins than those receiving total laryngectomy. Facility characteristics were not associated with differences in salvage surgery type or outcomes. Conclusion In recognition of the inherent selection bias, patients who experienced recurrences after radiation for T1/T2 larynx cancer and underwent conservation salvage laryngeal surgery demonstrated clinical outcomes similar to those of patients undergoing salvage total laryngectomy. Increased rates of positive surgical margins were observed among patients undergoing salvage conservation surgery.

Entities:  

Keywords:  NCDB; larynx cancer; outcomes; partial laryngectomy; survival; total laryngectomy

Mesh:

Year:  2018        PMID: 29292665     DOI: 10.1177/0194599817742596

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  5 in total

1.  Evaluation of Lymph Node Ratio Association With Long-term Patient Survival After Surgery for Node-Positive Merkel Cell Carcinoma.

Authors:  Shayan Cheraghlou; George O Agogo; Michael Girardi
Journal:  JAMA Dermatol       Date:  2019-07-01       Impact factor: 10.282

2.  Salvage surgery for recurrent larynx cancer.

Authors:  Ximena Mimica; Martin Hanson; Snehal G Patel; Marlena McGill; Sean McBride; Nancy Lee; Lara A Dunn; Jennifer R Cracchiolo; Jatin P Shah; Richard J Wong; Ian Ganly; Marc A Cohen
Journal:  Head Neck       Date:  2019-08-21       Impact factor: 3.147

3.  Surgical prevention of pharyngocutaneous fistula in salvage total laryngectomy: a systematic review and network meta-analysis.

Authors:  Armando De Virgilio; Andrea Costantino; Giuseppe Mercante; Fabio Ferreli; Bianca Maria Festa; Elena Russo; Luca Malvezzi; Raul Pellini; Giovanni Colombo; Giuseppe Spriano
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-06-22       Impact factor: 2.503

4.  Extracapsular extension is not a significant prognostic indicator in non-squamous cancers of the major salivary glands.

Authors:  Shayan Cheraghlou; Phoebe K Yu; Michael D Otremba; Saral Mehra; Wendell G Yarbrough; Benjamin L Judson
Journal:  Cancers Head Neck       Date:  2018-07-03

5.  Factors Associated with Outcomes Following Salvage Surgery for Recurrent Laryngeal Cancer: A Retrospective Study of 50 Cases from a Single Center in Poland.

Authors:  Katarzyna Miśkiewicz-Orczyk; Wojciech Ścierski; Grażyna Lisowska; Natalia Zięba; Maciej Misiołek
Journal:  Med Sci Monit       Date:  2021-09-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.